Based on the key indicators related to Novartis' liquidity, profitability, solvency, and operating efficiency, Novartis AG ADR is not in a good financial situation at this time. It has a very high probability of going through financial hardship in April. At this time, Novartis' Inventory is comparatively stable compared to the past year. Total Current Assets is likely to gain to about 30 B in 2025, whereas Other Current Liabilities is likely to drop slightly above 11.2 B in 2025. Key indicators impacting Novartis' financial strength include:
The essential information of the day-to-day investment outlook for Novartis includes many different criteria found on its balance sheet. An individual investor should monitor Novartis' cash flow, debt, and profitability to accurately make informed decisions on whether to invest in Novartis.
Please note, the imprecision that can be found in Novartis' accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Novartis AG ADR. Check Novartis' Beneish M Score to see the likelihood of Novartis' management manipulating its earnings.
Novartis Stock Summary
Novartis competes with AstraZeneca PLC, GlaxoSmithKline PLC, Roche Holding, Bristol Myers, and Sanofi ADR. Novartis AG researches, develops, manufactures, and markets healthcare products worldwide. The company was incorporated in 1996 and is headquartered in Basel, Switzerland. Novartis operates under Drug ManufacturersGeneral classification in the United States and is traded on New York Stock Exchange. It employs 108000 people.
Specialization
Health Care, Pharmaceuticals, Biotechnology & Life Sciences
The reason investors look at the income statement is to determine what Novartis' earnings per share (EPS) will be in order to see if they want to buy more shares or not. For example, if a company earned $20 million in the last quarter and has 100,000 shares outstanding, its EPS is 20 cents. If you find that this number beats analysts' forecasts or is higher than it was from the same period last year, then you might want to buy more of this stock even though its price per share may not have changed.
Comparative valuation techniques use various fundamental indicators to help in determining Novartis's current stock value. Our valuation model uses many indicators to compare Novartis value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Novartis competition to find correlations between indicators driving Novartis's intrinsic value. More Info.
Novartis AG ADR is regarded fifth in return on equity category among its peers. It also is regarded fifth in return on asset category among its peers reporting about 0.38 of Return On Asset per Return On Equity. The ratio of Return On Equity to Return On Asset for Novartis AG ADR is roughly 2.60 . At this time, Novartis' Return On Equity is comparatively stable compared to the past year. Comparative valuation analysis is a catch-all technique that is used if you cannot value Novartis by discounting back its dividends or cash flows. It compares the stock's price multiples to nearest competition to determine if the stock is relatively undervalued or overvalued.
Novartis AG ADR Systematic Risk
Novartis' systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. Novartis volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
The output start index for this execution was twenty with a total number of output elements of fourty-one. The Beta measures systematic risk based on how returns on Novartis AG ADR correlated with the market. If Beta is less than 0 Novartis generally moves in the opposite direction as compared to the market. If Novartis Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one Novartis AG ADR is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of Novartis is generally in the same direction as the market. If Beta > 1 Novartis moves generally in the same direction as, but more than the movement of the benchmark.
Novartis Thematic Clasifications
Novartis AG ADR is part of several thematic ideas from Healthcare to Compulsion. If you are a theme-oriented, socially responsible, and at the same time, a result-driven investor, you can align your investing habits with your values without jeopardizing your expectations about returns. You can easily create an optimal portfolio of stocks, ETFs, funds, or cryptocurrencies based on a specific theme of your liking. Get More Thematic Ideas
Today, most investors in Novartis Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Novartis' growth ratios. Consistent increases or decreases in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's growth growth rates may not be enough to decide which company is a better investment. That's why investors frequently use static breakdown of Novartis growth as a starting point in their analysis.
Along with financial statement analysis, the daily predictive indicators of Novartis help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of Novartis AG ADR. We use our internally-developed statistical techniques to arrive at the intrinsic value of Novartis AG ADR based on widely used predictive technical indicators. In general, we focus on analyzing Novartis Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Novartis's daily price indicators and compare them against related drivers.
When running Novartis' price analysis, check to measure Novartis' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Novartis is operating at the current time. Most of Novartis' value examination focuses on studying past and present price action to predict the probability of Novartis' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Novartis' price. Additionally, you may evaluate how the addition of Novartis to your portfolios can decrease your overall portfolio volatility.